Abstract 1717P
Background
Digitalisation of healthcare delivery enhances security, efficiency, and cost-effectiveness. The challenges of transitioning to a modern electronic healthcare system with multiple workflows remain poorly described, especially for early phase trial units. We present our recommendations for digital healthcare transition based on our experiences and outcomes. The Royal Marsden (RM) and Institute of Cancer Research (ICR) Drug Development Unit (DDU) is one of the largest early phase centres in Europe, enrolling ∼300 patients across >60 trials per year, with a dedicated ward, day unit and outpatient clinic.
Methods
In March 2023, RM transitioned to a new healthcare system. DDU adopted a patient centric approach, as per table, with emphasis on safe treatment delivery for patients within the dose-limiting toxicity (DLT) period. Table: 1717P
Planning aims
a) Virtual walk-through trial pathways from referral to discharge b) Patient visits planning and forecast for first 4 weeks. For Week 1, targeted reduction in planned patient attendance by 10% with no patients starting on trial and on-site attendance is prioritised for those within DLT period. c) Staff training < 8 weeks in advance and absences minimised during the transition period d) Managing expectations of patients, staff, and partners e) Daily team meetings to feedback and escalate issues |
Results
All planned trial activities were completed during weeks 1-4; though late IMP dosing up to 21:00 were experienced. Over these weeks, 36 patients were treated within the DLT period, and no safety issues raised. Adaptation pace among staff varied, with reports of fatigue from learning new workflows, improving from Week 4. From Week 5, the number of attendances returned to pre-transition levels.
Conclusions
Major digital transformation projects can be undertaken safely within a phase I trial setting whilst maintaining service delivery, with investments in implementation beyond the technology itself. Staff digital literacy assessments, training, pathway walkthrough, interface familiarisation, managing staff morale are critical for managing such transitions. Extensive planning and focus on the end users are vital in ensuring both short-term delivery and long-term benefits of digital transformation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Institute of Cancer Research and The Royal Marsden Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1706P - Time to full approval of novel anticancer medicines granted accelerated approval and implications for reform of the accelerated approval pathway
Presenter: Thomas Hwang
Session: Poster session 23
1707P - Cancer drug prices in the US: Efficacy, innovation, clinical trial evidence, and epidemiology
Presenter: Christoph Michaeli
Session: Poster session 23
1708P - The registration pathways in China for globally developed novel anticancer drugs
Presenter: Da-wei Wu
Session: Poster session 23
1709P - Influence of censoring on conclusions of FDA-approved cancer drugs using the modified time to treatment failure
Presenter: Jonathan Ofer
Session: Poster session 23
1710P - Protocol waivers and consequences on treatment safety and efficacy in the Drug Rediscovery Protocol (DRUP)
Presenter: Laurien Zeverijn
Session: Poster session 23
1711P - The DRUP-like clinical trials family: A distributed European trial network for equitable access to precision medicine
Presenter: Hans Gelderblom
Session: Poster session 23
1712P - Implementation of a molecular pre-screening program (MPP) in a network of public cancer centres for phase I clinical trial (Ph1-CT) candidates: The PREICO program
Presenter: Juan José Soto Castillo
Session: Poster session 23
1713P - Non-inferiority oncology clinical trials in major journals: Purposes, methods and results
Presenter: Rafael Barreto
Session: Poster session 23
1714P - Geographical disparities in access to cancer clinical trials in Korea
Presenter: Sokbom Kang
Session: Poster session 23
1715P - Analysis of the adequacy of control arms in oncology randomized clinical trials published between 2017 and 2021: A meta-research study
Presenter: Alessandro Rossi
Session: Poster session 23